List view / Grid view
If the proof-of concept trial of AVA6000 Pro-doxorubicin is successful,…
If the proof-of concept trial of AVA6000 Pro-doxorubicin is successful, it could lead to a pipeline of pro-drug chemotherapies with limited toxicity, say the drug's developers.
Deal marks Avacta’s entry to the third largest Asia-Pacific biotech…
27 September 2012 | By kdm communications limited
Deal marks Avacta’s entry to the third largest Asia-Pacific biotech market...
Avacta Group has expanded its Yorkshire headquarters with the addition…
29 June 2012 | By kdm communications limited
Avacta Group has expanded its Yorkshire headquarters with the addition of new laboratory, office and manufacturing space...
